Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity Study of V710 Lyophilized Formulation (V710-004)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 to 80 years of age~* Good physical health based upon medical history and physical examination~* Willing and able to participate in the entire study duration~* Female subject with a negative urine pregnancy test immediately prior to study vaccination~Exclusion Criteria:~* Chronic skin infections or a chronic skin condition (e.g. psoriasis)~* Serious S. aureus infection in the last 12 months~* Allergy to aluminum-containing substance taken in the body or to any other vaccine component~* Oral temperature equal to or greater than 100.4ºF (38.0ºC), within the past 2 days~* Participation in a prior V710 vaccine clinical study~* Participation in any other clinical study in the past 4 weeks, or during the 3-month study duration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): V710
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).